United States Drug Manufacturers - General news

02:41 16 Jul 2026

FirstWord PHARMA Market update Main company 🇺🇸 United States

Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push

The article reports that Sanofi and Lilly are investing in AdvanCell's $315 million radiopharmaceutical initiative. This significant backing from major pharmaceutical companies highlights growing interest and investment in radiopharmaceutical development. The collaboration aims to advance AdvanCell's efforts in this specialized area of medicine.

LLY main company SNY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

02:41 16 Jul 2026

Moomoo Earnings Main company 🇺🇸 United States

Earnings Preview: Novartis AG to Report Financial Results on July 21

Novartis AG (NYSE:NVS) is scheduled to announce its quarterly earnings results on Friday, July 21st. The company has a history of meeting or beating analyst estimates and currently has a consensus EPS estimate of $1.76 and a revenue estimate of $13.56 billion for the …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

02:40 16 Jul 2026

The Manila Times Earnings Main company 🇺🇸 United States

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation plc (NASDAQ: AMRN) has announced that it will release its second quarter 2026 financial results and host a conference call on Wednesday, July 29, 2026. The company will issue a press release before market hours, followed by a call with senior management …

AMRN main company

Sharemaestro market context Price below Trend Line 52 weeks -12.0%

01:41 16 Jul 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)?

Pfizer and Astellas recently secured FDA approval for PADCEV plus Keytruda for earlier-stage muscle-invasive bladder cancer, which broadens PADCEV’s application and reinforces Pfizer's oncology focus. While this strengthens Pfizer’s near-term cancer pipeline, the article notes that it doesn't fully mitigate the larger concerns of …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

01:10 16 Jul 2026

Businesskorea Deals and strategy Main company 🇺🇸 United States

Samsung Bioepis and Organon Broaden Biosimilar Access in Australia

Samsung Bioepis and Organon have expanded their collaboration in Australia to include an additional biosimilar, deepening their existing partnership. This agreement grants Organon exclusive commercial rights for the new biosimilar in Australia, while Samsung Bioepis retains development, manufacturing, and regulatory responsibilities. The expansion aims …

OGN main company

Sharemaestro market context Trend signal active 52 weeks +46.5%

23:07 15 Jul 2026

Stock Traders Daily Guidance Main company 🇺🇸 United States

(AMGN) Price Dynamics and Execution-Aware Positioning

This article provides an analysis of Amgen Inc. (NASDAQ: AMGN) stock, highlighting a weak near-term sentiment but strong long-term outlook. It details specific AI-generated trading strategies including long, breakout, and short positions with defined entry points, targets, and stop losses. The analysis also includes …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

22:10 15 Jul 2026

TipRanks Market update Main company 🇺🇸 United States

Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial

Novo Nordisk announced its ongoing Phase 3 clinical study, "Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity." This study investigates a new weekly injectable drug (NNC0487-0111) …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

21:38 15 Jul 2026

Stock Titan Earnings Main company 🇺🇸 United States

Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier

Gilead Sciences, Inc. (NASDAQ: GILD) shareholder Johanna Mercier plans to sell 3,000 common shares through Morgan Stanley Smith Barney LLC on July 15, 2026, for an aggregate value of approximately $389,757.60. These shares were acquired as performance shares on February 4, 2025. Mercier has …

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:25 15 Jul 2026

Investing.com Canada Market update Main company 🇺🇸 United States

Form 144 GILEAD SCIENCES For: 15 July By Investing.com

This article announces the filing of Form 144 for Gilead Sciences (GILD) on July 15. The brief notification is presented without further details but is relevant for investors tracking insider transactions. Gilead Sciences' stock is also noted with a 1.28% increase.

GILD main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

21:15 15 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Bristol-Myers Squibb Co Stock (BMY) Closed Up by 3.12% on Jul 15: Key Drivers Unveiled

Bristol-Myers Squibb Co (BMY) stock rose 3.12% on July 15, driven by positive late-stage clinical trial results, increased institutional inflows into the defensive pharmaceutical sector, and favorable technical indicators. Despite facing patent expirations and pricing negotiation risks, the company's diversification strategy and pipeline successes …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

21:14 15 Jul 2026

Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Novartis stock holds steady on its global drug pipeline

Novartis's stock remains stable, supported by its global drug pipeline and status as a major European drugmaker. The company's focus on innovative medicines across oncology, immunology, cardiovascular disease, and neuroscience provides a strong foundation for its recurring specialty-drug revenue and resilience in the market. …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2%

21:07 15 Jul 2026

Fox Business Earnings Main company 🇺🇸 United States

Johnson & Johnson commits to $55B, 4-year US investment plan

Johnson & Johnson's CFO Joe Wolk announced the company's commitment to a $55 billion, four-year investment plan in the US. Wolk discussed this plan, along with the company's Q2 earnings and the performance of its medical technology unit, including Impella heart pumps, during an …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

20:46 15 Jul 2026

Fierce Pharma Regulatory and legal Main company 🇺🇸 United States

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

Sanofi has initiated new patent infringement lawsuits against Pfizer and Moderna, targeting the lipid nanoparticle (LNP) technology used in their COVID-19 vaccines and Moderna's RSV vaccine. Sanofi claims the LNP tech, developed by its acquired Translate Bio, infringes on its patents related to mRNA …

SNY main company

Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1%

20:15 15 Jul 2026

Morningstar Earnings Main company 🇺🇸 United States

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility

Johnson & Johnson reported a 6.6% revenue growth in the second quarter, driven by strong performances in Innovative Medicine and MedTech, leading management to increase 2026 guidance. While shares dropped 2% intraday, Morningstar is maintaining its $190 fair value estimate, noting J&J's robust oncology …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

19:43 15 Jul 2026

Fierce Pharma Earnings Main company 🇺🇸 United States

Novo gains head start on Lilly with European Commission approval of Wegovy pill

Novo Nordisk has secured a head start over Eli Lilly in Europe with the European Commission's marketing authorization for the Wegovy pill for obesity and overweight adults. This approval makes it the first GLP-1 receptor available in tablet form in Europe. The European Commission …

LLY main company NVO main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%

18:56 15 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain

Johnson & Johnson is restructuring its pharmaceutical supply chain, announcing up to $750 million in costs to streamline operations, including offloading certain sites. This move follows a $55 billion commitment to bolster U.S. manufacturing capabilities for medicines in the U.S. The company reported strong …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

18:37 15 Jul 2026

Zacks Earnings Main company 🇺🇸 United States

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb (BMY) has seen a 1.8% return over the past month, slightly outperforming the S&P 500 composite. The company's earnings estimates have been revised upwards, with a Zacks Rank #3 (Hold), and it reported strong revenue and EPS beats in the last …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

18:25 15 Jul 2026

Benzinga Earnings Main company 🇺🇸 United States

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer

Merck announced that its blockbuster drug Keytruda outperformed chemotherapy in a Phase 3 trial for advanced or recurrent endometrial cancer, meeting its primary endpoint of progression-free survival. Keytruda is the first and only PD-1 inhibitor to show significant improvement as monotherapy in this patient …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

18:10 15 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Novo Nordisk wins EU approval for Wegovy weight-loss pill

Novo Nordisk has received EU approval for its once-daily Wegovy pill for weight management in adults with obesity or who are overweight, marking it as the first oral GLP-1 weight-loss treatment cleared for use across the EU. The approval, based on clinical trial data …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

18:08 15 Jul 2026

BioSpace Earnings Main company 🇺🇸 United States

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.34 per share for the third quarter of 2026. This dividend will be payable on September 8, 2026, to shareholders recorded by August 25, 2026. The ex-dividend date is also set for August …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

17:10 15 Jul 2026

Market source Earnings Main company 🇺🇸 United States

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb (BMY), a biopharmaceutical company within the Zacks Medical - Biomedical and Genetics industry, has a strong track record of surpassing earnings estimates in its last two reports, with an average surprise of 9.64%. With recent estimates moving higher and a positive …

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.1%

17:04 15 Jul 2026

Reuters Regulatory and legal Main company 🇺🇸 United States

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's patent rights, specifically those covering …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

16:45 15 Jul 2026

Simply Wall Street Regulatory and legal Main company 🇺🇸 United States

Amgen’s Tablet Recalls Test Its Quality Controls and Manufacturing Ambitions (AMGN)

Amgen recently initiated nationwide US recalls of certain Sensipar and Corlanor tablet lots due to FDA-identified manufacturing deviations and foreign substances. These Class II recalls raise concerns about Amgen's operational oversight and regulatory risk management, especially as the company aims to scale complex biologics …

AMGN main company

Sharemaestro market context Trend signal active 52 weeks +44.4%

16:38 15 Jul 2026

Quartz Earnings Main company 🇺🇸 United States

Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength

Johnson & Johnson reported strong Q2 2026 earnings, surpassing expectations with $25.31 billion in sales, primarily driven by its Innovative Medicine unit. The company also raised its full-year revenue outlook to $101.1 billion, a historic milestone. Growth in cancer and immunology drugs offset declines …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:34 15 Jul 2026

Proactive financial news Earnings Main company 🇺🇸 United States

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

Jefferies notes that strong Q2 sales of Johnson & Johnson's Spravato, a depression treatment, indicate a promising long-term commercial opportunity for psychedelic drugs in treating mental health disorders. The drug's annual revenue run rate of over $2.3 billion and its potential to reach $3 …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:13 15 Jul 2026

Market source Deals and strategy Main company 🇺🇸 United States

J&J raises FY26 outlook following positive Q2

Johnson & Johnson (J&J) reported strong Q2 revenues of $25.3 billion, a 6.6% year-over-year increase, primarily driven by its Innovative Medicine business and J&J MedTech. Following these results, the company raised its 2026 earnings outlook to $11.60-$11.75 per share. Despite the positive outlook, J&J's …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +48.8%

16:07 15 Jul 2026

TradingView Earnings Main company 🇺🇸 United States

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

Biogen's shares fell by 8.2% after presenting data from its phase II CELIA study for the experimental Alzheimer’s drug, diranersen, which failed to meet its primary endpoint. Although the drug showed meaningful reductions in cognitive decline, it did not demonstrate the expected dose-response relationship, …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

15:58 15 Jul 2026

Bloomberg Law News Market update Main company 🇺🇸 United States

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna Inc. and Pfizer Inc., seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that these vaccines infringe upon as many as 10 of its mRNA delivery patents. The lawsuits were filed in the US District …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:24 15 Jul 2026

Market source Regulatory and legal Main company 🇺🇸 United States

Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC

Pfizer and Astellas Pharma announced FDA approval of PADCEV plus Keytruda as a neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), marking the first platinum-free regimen approved for MIBC regardless of cisplatin eligibility. This approval expands on a previous FDA …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +8.9%

15:15 15 Jul 2026

TradingKey Earnings Main company 🇺🇸 United States

Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled

Merck & Co Inc (MRK) shares rose by 3.05% on July 15, driven by positive oncology clinical data and robust pipeline developments in its cardiovascular and immunology segments. Analysts have revised forecasts upward due to improved operational margins and strategic capital allocation, positioning healthcare …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +60.7%

14:41 15 Jul 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

GSK (NYSE: GSK) closes $10.6B Nuvalent deal to expand lung cancer pipeline

GSK has completed its $10.6 billion acquisition of Nuvalent, a clinical-stage biopharmaceutical company, significantly expanding its oncology pipeline. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655), which have FDA Breakthrough Therapy and Orphan Drug Designations and are expected to …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +26.3% · Next-week setup positive 55.6%

14:37 15 Jul 2026

Investing.com Market update Main company 🇺🇸 United States

Biogen names Michael Parini as chief legal officer

Biogen Inc. has appointed Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of experience in the biopharmaceutical industry, having previously served as CEO of Spur Therapeutics and held leadership roles at Vertex Pharmaceuticals and …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3%

14:10 15 Jul 2026

24/7 Wall St. Earnings Main company 🇺🇸 United States

Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?

Pfizer and Gilead Sciences are presenting a contrarian investment opportunity as both stocks have experienced "death crosses" but trade below Wall Street consensus targets. Pfizer appears to be the more compelling contrarian setup due to its attractive 8x forward P/E and 7% dividend yield, …

GILD main company PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +23.7%

13:53 15 Jul 2026

Seeking Alpha Market update Main company 🇺🇸 United States

Novo wins EU nod for Wegovy pill and higher-dose Wegovy in single-dose pen

Novo Nordisk has received marketing authorization from the European Commission for its Wegovy pill and a higher-dose version of the Wegovy injectable in a single-dose pen. This approval means the once-daily oral option will be available across 27 EU countries.

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:49 15 Jul 2026

Market source Earnings Main company 🇺🇸 United States

NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Novo Nordisk's oral Wegovy has received EU approval for weight management, causing NVO stock to jump 2.5%. This marks the fifth regulatory approval for the oral pill worldwide, and the company plans to launch it in more countries by late 2026. Retail investors have …

NVO main company

Sharemaestro market context Trend signal started 52 weeks -16.7%

13:13 15 Jul 2026

Quiver Quantitative Earnings Main company 🇺🇸 United States

VivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth Guidance

VivoSim Labs announced it received a $5 million milestone payment from Eli Lilly, tied to the progression of an inflammatory bowel disease drug into Phase 2 studies. The company also projects over 500% revenue growth for Fiscal Year 2027, driven by increasing demand for …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3%